Skip Navigation

Journal of Antimicrobial Chemotherapy 2005 55(Supplement 2):ii5-ii13; doi:10.1093/jac/dki004
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Finch, R. G.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finch, R. G.
Right arrow Articles by Eliopoulos, G. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Supplement

Safety and efficacy of glycopeptide antibiotics

R. G. Finch1 and G. M. Eliopoulos2,*

1 University of Nottingham, Nottingham, UK; 2 Department of Medicine, Beth Israel Deaconess Medical Centre, 330 Brookline Avenue, Boston, MA 02215, USA

* Corresponding author. Tel: +1-617-632-8586; Fax: +1-617-632-7442; Email: geliopou{at}bidmc.harvard.edu

It would be difficult to envision the practice of infectious diseases over the past 20 years without the availability of the glycopeptide antibiotics. The two agents currently in clinical use, vancomycin and teicoplanin, have proven remarkably versatile in many common applications. Several attributes of these agents account for this favourable profile: (i) their broad spectrum of activity against Gram-positive bacteria, including strains resistant to many other antimicrobials; (ii) their favourable pharmacokinetic properties that allow the once- or twice-daily dosing regimens that have made out-of-hospital therapy possible; and (iii) their generally good safety profiles which, along with their structural dissimilarity to ß-lactam and other antimicrobials, permits their use in many patients who are intolerant of other antibiotic regimens. It is not entirely surprising, therefore, that despite more than 40 years of clinical use and the interim appearance of bacterial strains resistant to this drug class, there remains continued interest in the development of newer members of the glycopeptide antibiotic class. This paper is intended to provide a global overview of the efficacy and safety of glycopeptide antibiotics currently in use, as background to understanding the need for and potential roles of new agents of this class.

Keywords: vancomycin , teicoplanin , oritavancin , dalbavancin , resistance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
R K Crowley, F Fitzpatrick, D Solanki, S FitzGerald, H Humphreys, and E G Smyth
Vancomycin administration: the impact of multidisciplinary interventions
J. Clin. Pathol., October 1, 2007; 60(10): 1155 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. P Pai, R.-C. Mercier, and S. A Koster
Epidemiology of Vancomycin-Induced Neutropenia in Patients Receiving Home Intravenous Infusion Therapy
Ann. Pharmacother., February 1, 2006; 40(2): 224 - 228.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.